Research graph
References from Structural biology in antiviral drug design. Local targets link to admitted publications; unresolved targets remain external evidence.
The HIV-1 capsid and reverse transcription
10.1186/s12977-021-00566-0 · 2021 · External reference
The molecular architecture of the nuclear pore complex
10.1038/nature06405 · 2007 · External reference
Unresolved reference
2002 · External reference
New approaches to the treatment of chronic hepatitis B
10.3390/jcm9103187 · 2020 · External reference
The process of structure-based drug design
10.1016/j.chembiol.2003.09.002 · 2003 · External reference
How cryo-EM is revolutionizing structural biology
10.1016/j.tibs.2014.10.005 · 2015 · External reference
Antivirals targeting the surface glycoproteins of influenza virus: mechanisms of action and resistance
10.3390/v13040624 · 2021 · External reference
Unresolved reference
External reference
A review of ligand-based virtual screening web tools and screening algorithms in large molecular databases in the age of big data
10.4155/fmc-2018-0076 · 2018 · External reference
Rational drug design: one target, many paths to it
2017 · External reference
Structural biology in antiviral drug discovery
10.1016/j.coph.2016.08.014 · 2016 · External reference
Combating emerging viral threats
10.1126/science.aaa3778 · 2015 · External reference
Unresolved reference
2012 · External reference
10.1504/ijista.2019.10021692
10.1504/ijista.2019.10021692 · 2019 · External reference
Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist
10.1128/jvi.79.20.12828-12839.2005 · 2005 · External reference
Action and reaction: the arthropod-borne flaviviruses and host interferon responses
10.2217/17460794.1.4.447 · 2006 · External reference
Artificial intelligence (AI) in drug design and discovery: a comprehensive review
10.1016/j.insi.2025.100049 · 2025 · External reference
High-throughput crystallography for lead discovery in drug design
10.1038/nrd706 · 2002 · External reference
Unresolved reference
1999 · External reference
RCSB protein data bank: powerful new tools for exploring 3D structures
10.1093/nar/gkaa1038 · 2021 · External reference
Nuclear magnetic resonance spectroscopy and imaging in animal research
10.1093/ilar.42.3.189 · 2001 · External reference
Turning protein crystallisation from an art into a science
10.1016/j.sbi.2004.08.002 · 2004 · External reference
Anti-SARS-CoV-2 activity of flavonoids Anti-SARS-CoV-2
2024 · External reference
Unresolved reference
2025 · External reference
QSAR modeling: where have you been? Where are you going to?
10.1021/jm4004285 · 2014 · External reference
Raltegravir: the first HIV integrase inhibitor
10.1016/j.clinthera.2008.10.012 · 2008 · External reference
Structural biology and drug discovery
10.1016/s1359-6446(05)03484-7 · 2005 · External reference
Unresolved reference
2024 · External reference
Prediction reliability of QSAR models: an overview of various validation tools
10.1007/s00204-022-03252-y · 2022 · External reference
Viral quasispecies
10.1371/journal.pgen.1008271 · 2019 · External reference
Advances and insights in the diagnosis of viral infections
10.1186/s12951-021-01081-2 · 2021 · External reference
Biomolecular simulation: A computational microscope for molecular biology
10.1146/annurev-biophys-042910-155245 · 2012 · External reference
Diffraction techniques in structural biology
10.1002/0471142700.nc0713s41 · 2010 · External reference
Nucleosides and nucleoside analogues as emerging antiviral drugs
10.2174/1570193x17999200820163234 · 2021 · External reference
Structure-based drug design; Computational strategies in drug discovery; antihypertensive agents; Antiviral drugs; molecular docking; QSAR; pharmacological insights
2026 · External reference
Structural analysis of anti-retroviral drug raltegravir and its potential impurity C: investigation of solubility and stability
10.1039/d3ce01071f · 2024 · External reference
Ribavirin: a clinical overview
10.1007/bf00152711 · 1986 · External reference
Molecular dynamics-driven drug discovery: leaping forward with confidence
10.1016/j.drudis.2016.11.001 · 2017 · External reference
Structure of the RNA-dependent RNA polymerase from COVID-19 virus
10.1126/science.abb7498 · 2020 · External reference
Unresolved reference
2025 · External reference
Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine
10.1086/317449 · 2000 · External reference
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease
10.1126/science.abf7945 · 2021 · External reference
Advancements in antiviral drug development: comprehensive insights into design strategies and mechanisms targeting key viral proteins
10.4014/jmb.2403.03008 · 2024 · External reference
Chem-bioinformatics: comparative QSAR at the interface between chemistry and biology
10.1021/cr0102009 · 2002 · External reference
The impact of structure-guided drug design on clinical agents
2003 · External reference
Dynamic personalities of proteins
10.1038/nature06522 · 2007 · External reference
The role of protein 3D-structures in the drug discovery process
2003 · External reference
A CRISPR-cas cure for HIV/AIDS
10.3390/ijms24021563 · 2023 · External reference
Antiviral drug resistance as an adaptive process
10.1093/ve/vew014 · 2016 · External reference
Structure-based design of SARS-CoV-2 papain-like protease inhibitors
10.1016/j.ejmech.2023.116011 · 2024 · External reference
Unresolved reference
External reference
Discovery of N-substituted oseltamivir derivatives as novel neuraminidase inhibitors with improved drug resistance profiles and favorable drug-like properties
10.1016/j.ejmech.2023.115275 · 2023 · External reference
Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management
10.1007/s00296-020-04749-4 · 2021 · External reference
Unresolved reference
2026 · External reference
Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
10.1038/s41467-022-29915-z · 2022 · External reference
Unresolved reference
2013 · External reference
AI-integrated QSAR modeling for enhanced drug discovery: from classical approaches to deep learning and structural insight
10.3390/ijms26199384 · 2025 · External reference
Methods for similarity-based virtual screening
10.5936/csbj.201302009 · 2013 · External reference
Oxadiazepinone HBV capsid assembly modulators
10.1016/j.bmcl.2021.128353 · 2021 · External reference
The resolution revolution
10.1126/science.1251652 · 2014 · External reference
Unresolved reference
2012 · External reference
Flaviviridae nonstructural proteins: the role in molecular mechanisms of triggering inflammation
10.3390/v14081808 · 2022 · External reference
Machine-learning approaches in drug discovery: methods and applications
10.1016/j.drudis.2014.10.012 · 2015 · External reference
Unresolved reference
2007 · External reference
CRISPR/Cas9-based antiviral strategy: current status and the potential challenge
10.3390/molecules24071349 · 2019 · External reference
The response of protein structures to amino-acid sequence changes
1986 · External reference
Unresolved reference
External reference
Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF
10.1073/pnas.0408824102 · 2005 · External reference
Zika virus circumvents host innate immunity by targeting the adaptor proteins MAVS and MITA
10.1096/fj.201900260r · 2019 · External reference
Blocking of interferon-induced Jak-Stat signaling by Japanese encephalitis virus NS5 through a protein tyrosine phosphatase-mediated mechanism
10.1128/jvi.02714-05 · 2006 · External reference
Structure-based virtual screening for drug discovery: principles, applications and recent advances
10.2174/1568026614666140929124445 · 2014 · External reference
New approaches in identifying drugs to inactivate oncogene products
10.1016/j.semcancer.2003.11.003 · 2004 · External reference
Role of computer-aided drug design in modern drug discovery
10.1007/s12272-015-0640-5 · 2015 · External reference
Glossary of terms used in computational drug design, part II (IUPAC Recommendations 2015)
10.1515/pac-2012-1204 · 2016 · External reference
Lamivudine salts with improved solubilities
10.1002/jps.23117 · 2012 · External reference
Oseltamivir: a review of its use in influenza
10.2165/00003495-200161020-00011 · 2001 · External reference
Molecular docking: a powerful approach for structure-based drug discovery
10.2174/157340911795677602 · 2011 · External reference
Unresolved reference
External reference
Immune responses to viruses
10.1016/b978-0-323-04404-2.10027-2 · 2008 · External reference
The expanding toolkit for structural biology: synchrotrons, X-ray lasers and cryoEM
10.1107/s2052252519002422 · 2019 · External reference
Inhibition of interferon signaling by dengue virus
10.1073/pnas.2335168100 · 2003 · External reference
Immune response to dengue virus and prospects for a vaccine
10.1146/annurev-immunol-031210-101315 · 2011 · External reference
SCOP: A structural classification of proteins database for the investigation of sequences and structures
10.1016/s0022-2836(05)80134-2 · 1995 · External reference
Efficient inhibition of HIV using CRISPR/Cas13d nuclease system
10.3390/v13091850 · 2021 · External reference
Computational drug discovery
10.1038/aps.2012.109 · 2012 · External reference
Salmonella suppresses the TRIF-dependent type I interferon response in macrophages
10.1128/mbio.02051-15 · 2016 · External reference
Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV
10.1056/nejmoa2101609 · 2021 · External reference
Artificial intelligence in drug discovery and development
10.1016/j.drudis.2020.10.010 · 2021 · External reference
A structural model for the retroviral proteases
10.1038/329351a0 · 1987 · External reference
Design and preparation of a 4:1 lamivudine–oxalic acid CAB cocrystal for improving the lamivudine purification process
10.1021/cg5005825 · 2014 · External reference
Unresolved reference
2004 · External reference
Virus structure and structure-based antivirals
10.1016/j.coviro.2021.09.005 · 2021 · External reference
Acute infection of viral pathogens and their innate immune escape
10.3389/fmicb.2021.672026 · 2021 · External reference
Unresolved reference
2025 · External reference
RIG-I-like receptors: their regulation and roles in RNA sensing
10.1038/s41577-020-0288-3 · 2020 · External reference
Novel atomic-level-based ai topological descriptors: application to QSPR/QSAR modeling
10.1021/ci020362l · 2002 · External reference
Unresolved reference
2020 · External reference
Unresolved reference
2006 · External reference
Unresolved reference
2018 · External reference
Unresolved reference
2015 · External reference
New roles for structure in biology and drug discovery
10.1038/80691 · 2000 · External reference
Repurposing an antiviral drug against SARS-CoV-2 main protease
10.1002/anie.202107481 · 2021 · External reference
Molecular dynamics simulations in drug discovery and drug delivery
2020 · External reference
A beginner's guide to cryogenic electron microscopy
10.1042/bio04102046 · 2019 · External reference
Structural biology and drug discovery
10.2174/138161206777585201 · 2006 · External reference
Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection
10.1056/nejmoa2115542 · 2022 · External reference
Structure based drug designing approaches in SARS-CoV-2 spike inhibi-tor design
10.2174/1568026623666221103091658 · 2022 · External reference
Unresolved reference
External reference
Advances in hepatitis B therapeutics
10.1177/2049936120965027 · 2020 · External reference
Crystallography and drug design
10.1007/s12045-014-0135-6 · 2014 · External reference
Ritonavir
2023 · External reference
Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly
10.1016/j.virusres.2019.197677 · 2019 · External reference
Biophysical applications in structural and molecular biology
10.1515/hsz-2021-0232 · 2021 · External reference
Overcoming antimicrobial resistance of the skin
10.1007/978-3-030-68321-4 · 2021 · External reference
Unresolved reference
2020 · External reference
Unresolved reference
External reference
Development of neuraminidase inhibitors as anti-influenza virus drugs
10.1002/(sici)1098-2299(199903/04)46:3/4<176::aid-ddr4>3.0.co;2-6 · 1999 · External reference
Advanced technologies for protein complex production and characterization: volume II
10.1007/978-3-031-52193-5_14 · 2024 · External reference
Cryo-electron microscopy and X-ray crystallography: complementary approaches to structural biology and drug discovery
2017 · External reference
Role of the development scientist in compound lead selection and optimization
10.1002/(sici)1520-6017(200002)89:2<145::aid-jps2>3.0.co;2-6 · 2000 · External reference
Unresolved reference
2011 · External reference
A review on crystallography and its role on drug design
2024 · External reference
How cryo-electron microscopy and X-ray crystallography complement each other
10.1002/pro.3022 · 2017 · External reference
Molecular docking for drug discovery and development: a widely used approach but far from perfect
10.4155/fmc-2016-0143 · 2016 · External reference
Elbasvir and grazoprevir for the treatment of hepatitis C
10.1080/14787210.2021.1874351 · 2021 · External reference
Advancements in antiviral drug development: comprehensive insights into design strategies and mechanisms targeting key viral proteins
10.4014/jmb.2403.03008 · 2024 · External reference
MAVS: the next STING in cancers and other diseases
10.1016/j.critrevonc.2024.104610 · 2025 · External reference
Integrative structural biology
10.1126/science.1228565 · 2013 · External reference
Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank
10.1111/febs.15366 · 2020 · External reference
Cryo-EM structure of the SARS-CoV-2 spike protein
10.1126/science.abb2507 · 2020 · External reference
How RIG-I like receptors activate MAVS
10.1016/j.coviro.2015.04.004 · 2015 · External reference
HIV-1 entry and membrane fusion inhibitors
10.3390/v13050735 · 2021 · External reference
Structural biology of SARS-CoV-2 and implications for therapeutic development
10.1038/s41579-021-00630-8 · 2021 · External reference
Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2
10.1039/d3ra06479d · 2023 · External reference
Unresolved reference
External reference
An alternative method for the evaluation of docking performance: RSR vs RMSD
10.1021/ci800084x · 2008 · External reference
Virtual screening of small molecular inhibitors against DprE1
10.3390/molecules23030524 · 2018 · External reference
Development of neuraminidase inhibitors as anti-influenza virus drugs
10.1002/(sici)1098-2299(199903/04)46:3/4<176::aid-ddr4>3.0.co;2-6 · ExternalCitation · doi-reference
Role of the development scientist in compound lead selection and optimization
10.1002/(sici)1520-6017(200002)89:2<145::aid-jps2>3.0.co;2-6 · ExternalCitation · doi-reference
Diffraction techniques in structural biology
10.1002/0471142700.nc0713s41 · ExternalCitation · doi-reference
Repurposing an antiviral drug against SARS-CoV-2 main protease
10.1002/anie.202107481 · ExternalCitation · doi-reference
Lamivudine salts with improved solubilities
10.1002/jps.23117 · ExternalCitation · doi-reference
How cryo-electron microscopy and X-ray crystallography complement each other
10.1002/pro.3022 · ExternalCitation · doi-reference
Overcoming antimicrobial resistance of the skin
10.1007/978-3-030-68321-4 · ExternalCitation · doi-reference
Advanced technologies for protein complex production and characterization: volume II
10.1007/978-3-031-52193-5_14 · ExternalCitation · doi-reference
Ribavirin: a clinical overview
10.1007/bf00152711 · ExternalCitation · doi-reference
Prediction reliability of QSAR models: an overview of various validation tools
10.1007/s00204-022-03252-y · ExternalCitation · doi-reference
Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management
10.1007/s00296-020-04749-4 · ExternalCitation · doi-reference
Crystallography and drug design
10.1007/s12045-014-0135-6 · ExternalCitation · doi-reference
Role of computer-aided drug design in modern drug discovery
10.1007/s12272-015-0640-5 · ExternalCitation · doi-reference
Immune responses to viruses
10.1016/b978-0-323-04404-2.10027-2 · ExternalCitation · doi-reference
Oxadiazepinone HBV capsid assembly modulators
10.1016/j.bmcl.2021.128353 · ExternalCitation · doi-reference
The process of structure-based drug design
10.1016/j.chembiol.2003.09.002 · ExternalCitation · doi-reference
Raltegravir: the first HIV integrase inhibitor
10.1016/j.clinthera.2008.10.012 · ExternalCitation · doi-reference
Structural biology in antiviral drug discovery
10.1016/j.coph.2016.08.014 · ExternalCitation · doi-reference
How RIG-I like receptors activate MAVS
10.1016/j.coviro.2015.04.004 · ExternalCitation · doi-reference
Virus structure and structure-based antivirals
10.1016/j.coviro.2021.09.005 · ExternalCitation · doi-reference
MAVS: the next STING in cancers and other diseases
10.1016/j.critrevonc.2024.104610 · ExternalCitation · doi-reference
Machine-learning approaches in drug discovery: methods and applications
10.1016/j.drudis.2014.10.012 · ExternalCitation · doi-reference
Molecular dynamics-driven drug discovery: leaping forward with confidence
10.1016/j.drudis.2016.11.001 · ExternalCitation · doi-reference
Artificial intelligence in drug discovery and development
10.1016/j.drudis.2020.10.010 · ExternalCitation · doi-reference
Discovery of N-substituted oseltamivir derivatives as novel neuraminidase inhibitors with improved drug resistance profiles and favorable drug-like properties
10.1016/j.ejmech.2023.115275 · ExternalCitation · doi-reference
Structure-based design of SARS-CoV-2 papain-like protease inhibitors
10.1016/j.ejmech.2023.116011 · ExternalCitation · doi-reference
Artificial intelligence (AI) in drug design and discovery: a comprehensive review
10.1016/j.insi.2025.100049 · ExternalCitation · doi-reference
Turning protein crystallisation from an art into a science
10.1016/j.sbi.2004.08.002 · ExternalCitation · doi-reference
New approaches in identifying drugs to inactivate oncogene products
10.1016/j.semcancer.2003.11.003 · ExternalCitation · doi-reference
How cryo-EM is revolutionizing structural biology
10.1016/j.tibs.2014.10.005 · ExternalCitation · doi-reference
Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly
10.1016/j.virusres.2019.197677 · ExternalCitation · doi-reference
SCOP: A structural classification of proteins database for the investigation of sequences and structures
10.1016/s0022-2836(05)80134-2 · ExternalCitation · doi-reference
Structural biology and drug discovery
10.1016/s1359-6446(05)03484-7 · ExternalCitation · doi-reference
Design and preparation of a 4:1 lamivudine–oxalic acid CAB cocrystal for improving the lamivudine purification process
10.1021/cg5005825 · ExternalCitation · doi-reference
Novel atomic-level-based ai topological descriptors: application to QSPR/QSAR modeling
10.1021/ci020362l · ExternalCitation · doi-reference
An alternative method for the evaluation of docking performance: RSR vs RMSD
10.1021/ci800084x · ExternalCitation · doi-reference
Chem-bioinformatics: comparative QSAR at the interface between chemistry and biology
10.1021/cr0102009 · ExternalCitation · doi-reference
QSAR modeling: where have you been? Where are you going to?
10.1021/jm4004285 · ExternalCitation · doi-reference
A structural model for the retroviral proteases
10.1038/329351a0 · ExternalCitation · doi-reference
New roles for structure in biology and drug discovery
10.1038/80691 · ExternalCitation · doi-reference
Computational drug discovery
10.1038/aps.2012.109 · ExternalCitation · doi-reference
The molecular architecture of the nuclear pore complex
10.1038/nature06405 · ExternalCitation · doi-reference
Dynamic personalities of proteins
10.1038/nature06522 · ExternalCitation · doi-reference
High-throughput crystallography for lead discovery in drug design
10.1038/nrd706 · ExternalCitation · doi-reference
Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
10.1038/s41467-022-29915-z · ExternalCitation · doi-reference
RIG-I-like receptors: their regulation and roles in RNA sensing
10.1038/s41577-020-0288-3 · ExternalCitation · doi-reference
Structural biology of SARS-CoV-2 and implications for therapeutic development
10.1038/s41579-021-00630-8 · ExternalCitation · doi-reference
Structural analysis of anti-retroviral drug raltegravir and its potential impurity C: investigation of solubility and stability
10.1039/d3ce01071f · ExternalCitation · doi-reference
Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2
10.1039/d3ra06479d · ExternalCitation · doi-reference
A beginner's guide to cryogenic electron microscopy
10.1042/bio04102046 · ExternalCitation · doi-reference
Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV
10.1056/nejmoa2101609 · ExternalCitation · doi-reference
Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection
10.1056/nejmoa2115542 · ExternalCitation · doi-reference
Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF
10.1073/pnas.0408824102 · ExternalCitation · doi-reference
Inhibition of interferon signaling by dengue virus
10.1073/pnas.2335168100 · ExternalCitation · doi-reference
Elbasvir and grazoprevir for the treatment of hepatitis C
10.1080/14787210.2021.1874351 · ExternalCitation · doi-reference
Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine
10.1086/317449 · ExternalCitation · doi-reference
Nuclear magnetic resonance spectroscopy and imaging in animal research
10.1093/ilar.42.3.189 · ExternalCitation · doi-reference
RCSB protein data bank: powerful new tools for exploring 3D structures
10.1093/nar/gkaa1038 · ExternalCitation · doi-reference
Antiviral drug resistance as an adaptive process
10.1093/ve/vew014 · ExternalCitation · doi-reference
Zika virus circumvents host innate immunity by targeting the adaptor proteins MAVS and MITA
10.1096/fj.201900260r · ExternalCitation · doi-reference
The expanding toolkit for structural biology: synchrotrons, X-ray lasers and cryoEM
10.1107/s2052252519002422 · ExternalCitation · doi-reference
Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank
10.1111/febs.15366 · ExternalCitation · doi-reference
Integrative structural biology
10.1126/science.1228565 · ExternalCitation · doi-reference
The resolution revolution
10.1126/science.1251652 · ExternalCitation · doi-reference
Combating emerging viral threats
10.1126/science.aaa3778 · ExternalCitation · doi-reference
Cryo-EM structure of the SARS-CoV-2 spike protein
10.1126/science.abb2507 · ExternalCitation · doi-reference
Structure of the RNA-dependent RNA polymerase from COVID-19 virus
10.1126/science.abb7498 · ExternalCitation · doi-reference
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease
10.1126/science.abf7945 · ExternalCitation · doi-reference
Blocking of interferon-induced Jak-Stat signaling by Japanese encephalitis virus NS5 through a protein tyrosine phosphatase-mediated mechanism
10.1128/jvi.02714-05 · ExternalCitation · doi-reference
Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist
10.1128/jvi.79.20.12828-12839.2005 · ExternalCitation · doi-reference
Salmonella suppresses the TRIF-dependent type I interferon response in macrophages
10.1128/mbio.02051-15 · ExternalCitation · doi-reference
Biomolecular simulation: A computational microscope for molecular biology
10.1146/annurev-biophys-042910-155245 · ExternalCitation · doi-reference
Immune response to dengue virus and prospects for a vaccine
10.1146/annurev-immunol-031210-101315 · ExternalCitation · doi-reference
Advances in hepatitis B therapeutics
10.1177/2049936120965027 · ExternalCitation · doi-reference
Advances and insights in the diagnosis of viral infections
10.1186/s12951-021-01081-2 · ExternalCitation · doi-reference
The HIV-1 capsid and reverse transcription
10.1186/s12977-021-00566-0 · ExternalCitation · doi-reference
Viral quasispecies
10.1371/journal.pgen.1008271 · ExternalCitation · doi-reference
10.1504/ijista.2019.10021692
10.1504/ijista.2019.10021692 · ExternalCitation · doi-reference
Biophysical applications in structural and molecular biology
10.1515/hsz-2021-0232 · ExternalCitation · doi-reference
Glossary of terms used in computational drug design, part II (IUPAC Recommendations 2015)
10.1515/pac-2012-1204 · ExternalCitation · doi-reference
Oseltamivir: a review of its use in influenza
10.2165/00003495-200161020-00011 · ExternalCitation · doi-reference
Structural biology and drug discovery
10.2174/138161206777585201 · ExternalCitation · doi-reference
Structure-based virtual screening for drug discovery: principles, applications and recent advances
10.2174/1568026614666140929124445 · ExternalCitation · doi-reference
Structure based drug designing approaches in SARS-CoV-2 spike inhibi-tor design
10.2174/1568026623666221103091658 · ExternalCitation · doi-reference
Nucleosides and nucleoside analogues as emerging antiviral drugs
10.2174/1570193x17999200820163234 · ExternalCitation · doi-reference
Molecular docking: a powerful approach for structure-based drug discovery
10.2174/157340911795677602 · ExternalCitation · doi-reference
Action and reaction: the arthropod-borne flaviviruses and host interferon responses
10.2217/17460794.1.4.447 · ExternalCitation · doi-reference
Acute infection of viral pathogens and their innate immune escape
10.3389/fmicb.2021.672026 · ExternalCitation · doi-reference
A CRISPR-cas cure for HIV/AIDS
10.3390/ijms24021563 · ExternalCitation · doi-reference
AI-integrated QSAR modeling for enhanced drug discovery: from classical approaches to deep learning and structural insight
10.3390/ijms26199384 · ExternalCitation · doi-reference
New approaches to the treatment of chronic hepatitis B
10.3390/jcm9103187 · ExternalCitation · doi-reference
Virtual screening of small molecular inhibitors against DprE1
10.3390/molecules23030524 · ExternalCitation · doi-reference
CRISPR/Cas9-based antiviral strategy: current status and the potential challenge
10.3390/molecules24071349 · ExternalCitation · doi-reference
Antivirals targeting the surface glycoproteins of influenza virus: mechanisms of action and resistance
10.3390/v13040624 · ExternalCitation · doi-reference
HIV-1 entry and membrane fusion inhibitors
10.3390/v13050735 · ExternalCitation · doi-reference
Efficient inhibition of HIV using CRISPR/Cas13d nuclease system
10.3390/v13091850 · ExternalCitation · doi-reference
Flaviviridae nonstructural proteins: the role in molecular mechanisms of triggering inflammation
10.3390/v14081808 · ExternalCitation · doi-reference
Advancements in antiviral drug development: comprehensive insights into design strategies and mechanisms targeting key viral proteins
10.4014/jmb.2403.03008 · ExternalCitation · doi-reference
Molecular docking for drug discovery and development: a widely used approach but far from perfect
10.4155/fmc-2016-0143 · ExternalCitation · doi-reference
A review of ligand-based virtual screening web tools and screening algorithms in large molecular databases in the age of big data
10.4155/fmc-2018-0076 · ExternalCitation · doi-reference
Methods for similarity-based virtual screening
10.5936/csbj.201302009 · ExternalCitation · doi-reference
